All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Research at Reunion Neuroscience Inc. has led to the discovery of benzyltryptamine compounds acting as 5-HT2A receptor agonists. These compounds are reported to be useful for the treatment of depression, alcoholism, cocaine addiction, inflammation, cluster headache neurological and post-traumatic stress disorder.